Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
esophageal cancer
Pharma
FDA limits Keytruda, Opdivo uses in stomach cancer
The two PD-1 inhibitors' FDA labels in gastric, gastroesophageal junction and esophageal cancers have been reduced to PD-L1-positive tumors only.
Angus Liu
Jun 9, 2025 10:50am
Merck, Eisai combo misses survival goal in GI cancer trial
Jan 24, 2025 10:26am
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
Oct 4, 2024 10:37am
Lucid recruits NFL alums for esophageal precancer testing blitz
Oct 2, 2024 11:20am
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
